Christopher Vreeland
Family · Atlanta, GANPI 1801877469
Payments from drug & device makers
Across 606 payments — averaging $28.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Senseonics, Incorporated$3K
- Medtronic$2K
- Novo Nordisk$2K
- Abbott$1K
- Mannkind Corporation$981
- BETA Bionics, Inc.$777
- plus $7K from 38 others
What the payments were for
- Consulting fees$5003%
- Speaking & faculty fees$3,44020%
- Travel & lodging$1,5239%
- Food & beverage$11,80368%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Eversense$3,440
- MINIMED 780G$1,756
- iLet Bionic Pancreas$1,385
- UNITY DIABETES MANAGEMENT SYSTEM$614
- CeQur Simplicity$342
- AFREZZA$294
- DEXCOM G6 TRANSMITTER$124
- RECORLEV$107
How this compares
$17,270 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 224 | $306,985 |
| MounjaroTirzepatide | 189 | $275,816 |
| TrulicityDulaglutide | 59 | $99,964 |
| JardianceEmpagliflozin | 104 | $90,007 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 20 | $68,248 |
| Tresiba Flextouch U-100Insulin Degludec | 78 | $67,947 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 74 | $64,594 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $59,855 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $52,440 |
| FarxigaDapagliflozin Propanediol | 28 | $42,868 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $38,929 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 25 | $36,007 |
| InvokanaCanagliflozin | 20 | $23,893 |
| FiaspInsulin Aspart (Niacinamide) | 12 | $22,526 |
| JanuviaSitagliptin Phosphate | 17 | $22,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $538 | $391,887279 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $1,661 | $346,282282 claims |
| Boehringer IngelheimJardiance | $224 | $90,007104 claims |
| AstraZenecaFarxiga | $127 | $42,86828 claims |
| MerckJanuvia, Janumet | $29 | $39,25128 claims |
| AbbVieSynthroid | $166 | $3,15430 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $132 | $2,829102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Atlanta
- Stacey TatroeAtlanta$38K
- Brandy HughesAtlanta$29K
- Cecile MartinAtlanta$23K
- Terri CowanAtlanta$21K
- Brandi Pinckney-GreeneAtlanta$18K
- Michelle SarievAtlanta$18K
- Angelica MillerAtlanta$15K
- Andrea Jefferson SaboorAtlanta$14K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.